Indivior Share Discussion Threads

[gregmorg] 14/2/2019 16:22

Steeplejack. The only really positive thing to say about today's events is that I see AZN reacted rather well to your latest purchase!

[florenceorbis] 14/2/2019 14:43

www.proactiveinvestors.co.uk/companies/news/214634/indivior-still-confident-in-blockbuster-potential-of-next-gen-opioid-addiction-treatment-214634.html

[steeplejack] 14/2/2019 10:31

Hi Greg,trust you're fighting fit.I've held AZN for a good while but added a few today.Been buying some Glaxo too but maybe a bit premature.I might be getting a tad old to double guess the likes of Indivior!My gut feel is that they'll probably make a success of Sublocade but there's many a slip between cup and lip.

[gregmorg] 14/2/2019 09:32

Steeplejack I am delighted you are joining the AZN camp as its good to see a like minded investor. Having said that I am unlikely to add value on comment on that one.
!
Yes Indivior looks as it it could be crawling off its sick bed but I will wait for the webcast, digest and probably wait a period beyond that before I get my head around the nuances. Been tripped up a tad here. Topped up below a pound but still my average price is somewhat above where we are now- said he as an understatement! Still travelling so that's okayish.

[rafieh] 14/2/2019 08:10

It appears that the market has already priced in the weak results and the previous news about the court case.

[grupo] 12/2/2019 08:21

Oliver Haill
WebFG News
12 Feb, 2019 07:48 12 Feb, 2019 07:57
Indivior applies to Supreme Court to block generic rivals
us supreme court
Indivior
104.65
08:04:03 12/02/19
2.65%
-2.40

Indivior said it will petition the US Supreme Court to block a decision by the Court of Appeals of the Federal Circuit to allow other companies to sell their generic versions of its anti-opioid treatment.
FTSE 250
18,855.99
08:04:07 12/02/19
0.13%
24.21
FTSE 350
3,965.49
08:04:07 12/02/19
0.30%
11.81
FTSE All-Share
3,912.11
08:04:07 12/02/19
0.28%
10.99

The FTSE 250 company said it assumes that both Dr Reddy's Laboratories and Alvogen Pine Brook will both launch their copycat versions of its Suboxone Film "at risk" of pending court judgments that they are infringing on Indivior's patents.

Last week Indivior warned that it could lose 80% of market share “in a matter of months” to generic versions of Suboxone after the appeals court denied its motion for rehearing. The company said it had instigated its contingency plan to cut debt and some operating expenses to help preserve its cash balance.

After the appeals court issued a mandate lifting a previous hold over the generic drugs based on US patent number 9,931,305, Indivior applied for a motion to stay the issuance of the mandate. This was denied.

Indivior then filed an emergency motion to hold the mandate while it made an application to the Supreme Court. This was also denied.

The court of appeal said that the generic versions of buprenorphine/naloxone sublingual film could be sold from 19 February 2019, leading Indivior to say it will file a petition to block this mandate with the Supreme Court.

Suboxone provides the bulk of revenues for Indivior, though the company last year launched a monthly injectable anti-opioid addiction treatment, though sales have been slow to build, and is planning to launch a new schizophrenia treatment this year.

[pre] 08/2/2019 09:20

The CAFC mandate is currently set to issue on February 11, 2019, so hopefully we wont get a huge markdown as last time albeit it probably will be marked down once rns is confirmed:-(

[grupo] 05/2/2019 11:01

-Indivior has suffered a new legal setback after a U.S. court denied it a motion for a rehearing in its case against Dr. Reddy's, sending shares plunging.

--Both Dr. Reddy's and Alvogen are set to bring generic versions of Indivior's Suboxone to the market following final confirmation by the courts.

--Indivior has launched its contingency plans as it attempts to conserve cash and bring down spending.



Indivior PLC (INDV.LN) said Tuesday that a U.S. court has denied its motion for a rehearing, following the court's decision to annul a preliminary injunction granted against Dr. Reddy's Laboratories Ltd. (500124.BY) which barred the Indian pharmaceutical from selling a generic version of Indivior's opioid-addiction treatment.

The U.K.-listed pharmaceutical company is in a legal battle to stop rivals from bringing to market generic alternatives of its Suboxone drug-addiction medication. The company alleges that the Indian company Dr. Reddy's, as well as competitor Alvogen, are infringing on its patents.

Indivior had previously been granted a stop-order against Dr. Reddy's barring it from selling its Suboxone generic, but this was overturned in November, sending shares of the company plummeting. Since then it's engaged with the courts to have the decision revoked.

Indivior said that, following this latest legal setback, the court is set to issue a mandate on Feb. 11 that formally vacates the preliminary injunction. It anticipates that Dr. Reddy's will resume the launch of its U.S. product on that date. Given an agreement it struck with Alvogen on Monday, the U.S. rival will also begin selling its version of Suboxone starting Feb. 11.

Indivior said that, based on precedent, this could result in Suboxone losing 80% of its market share in a matter of months.

The company said it has started implementing parts of its contingency plan announced in December, which involves bringing down debt and cutting its headcount as it attempts to conserve cash. Indivior said that it has plans to bring to market its own generic Suboxone to counter rivals' launch.

Shares of Indivior at 0806 GMT were down 23.05 pence, or 20%, to 90.10 pence.



Write to Carlo Martuscelli at [e-mail]



(END) Dow Jones Newswires

February 05, 2019 03:44 ET (08:44 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.

[dealy] 05/2/2019 09:28

great recovery.

[la forge] 05/2/2019 09:07

The pill – called Arbaclofen Placarbil

ANY RECENT UPDATES REGARDING THIS DRUG

[rafieh] 05/2/2019 08:49

PWhite,Have you shorted these at the bottom by any chance?

[dealy] 05/2/2019 08:47

That is total nonsense. The courts made decisions not Indivior.

[pwhite73] 05/2/2019 08:39

dealy

Yes that's right they followed a legal process that failed. However it does not change the fact that Dr Reddy's lost millions whilst the courts imposed a ban on the sale of their drug. Dr Reddy's has now won the case. The next stage will be to seek damages. This is standard practise. Watch for more RNS's relating to this case.

[rafieh] 05/2/2019 08:36

Two brokers who recommended these as 'buy' a couple of months ago did so assuming this court case was already lost.

[dealy] 05/2/2019 08:35

They didn't burn down their factories. They followed the legal process

[pwhite73] 05/2/2019 08:32

Instead of making bland statements go read the two rulings. Dr Reddy's was forced to halt the sale of its generic drug due to the legal action started by Indivior. The courts have ruled there was no patent infringement!!.

[dealy] 05/2/2019 08:23

how can Dr. Reddy seek damages from Indivior? Ludicrous statement

[pwhite73] 05/2/2019 08:20

rafieh It doesn't end here. Dr Reddy's can now turn the tables on Indivior and seek damages. Do you have any idea how much money this legal case has cost them in terms of loss revenue and reputation. There is nowhere else for Indivior to go other than the Supreme Court of the United States. If the court even decides to hear their case it won't be for another 5 - 8 years. Don't chase the stock.

[rafieh] 05/2/2019 08:12

This was always expected and therefore largely reflected in the share price that's why we are not below the previous low.

[pwhite73] 05/2/2019 07:55

Well don't say you weren't warned. The US Courts will never rule against any company listed on the US stock exchange in favour of companies that aren't. Size also matters. Dr Reddy's has 23,000 employees. Indivior just 1,000. Despite its own size the end for Indivior will be swift.